Evidence map›Paper›PMID 41004342›Full record

ArticleCell reports2025

GATA2 decommissioning of enhancers: A mechanism to constrain inflammatory signaling.

Mabel M Jung, Vu L Tran, Yue Xiong, Kirby D Johnson, Koichi R Katsumura, Peng Liu, Emery H Bresnick

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mabel M JungWisconsin Blood Cancer Research Institute, Department of Cell and Regenerative Biology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Carbone Cancer Center, Madison, WI, USA.
Vu L TranWisconsin Blood Cancer Research Institute, Department of Cell and Regenerative Biology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Carbone Cancer Center, Madison, WI, USA.
Yue XiongWisconsin Blood Cancer Research Institute, Department of Cell and Regenerative Biology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Carbone Cancer Center, Madison, WI, USA.
Kirby D JohnsonWisconsin Blood Cancer Research Institute, Department of Cell and Regenerative Biology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Carbone Cancer Center, Madison, WI, USA.
Koichi R KatsumuraWisconsin Blood Cancer Research Institute, Department of Cell and Regenerative Biology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Carbone Cancer Center, Madison, WI, USA.
Peng LiuCarbone Cancer Center, Madison, WI, USA; Department of Biostatistics and Biomedical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Emery H BresnickWisconsin Blood Cancer Research Institute, Department of Cell and Regenerative Biology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Carbone Cancer Center, Madison, WI, USA. Electronic address: ehbresni@wisc.edu.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
RESEARCH TRAINING IN HEMATOLOGYT32HL007899 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI Jane Ellen Churpek · 1998 to 2026
$8.2M
Hematopoietic Regulation via GATA SwitchesR01DK068634 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI Emery H. Bresnick · 2006 to 2026
$7.5M
The role of inflammation in driving leukemogenesis in germline predisposition syndromesU01CA257666 · NCI · UNIVERSITY OF CHICAGO · PI AGARWAL, ANUPRIYA, BRESNICK, EMERY H. · 2022 to 2025
$2.5M
Linking GATA2 deficiency to innate immune signalingF31DK138794 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI TRAN, VU LE-HUY · 2024 to 2024
$36k
NCI NIH HHS P30 CA014520NCI NIH HHS U01 CA257666NHLBI NIH HHS T32 HL007899NIDDK NIH HHS F31 DK138794NIDDK NIH HHS R01 DK068634
6 · The paper itself

Abstract

GATA2 establishes transcriptomes governing hematopoietic stem/progenitor cell development. In progenitors, GATA2 represses inflammatory genes (Il6st and Il6ra) encoding IL6ST/GP130 and IL6RA receptor subunits mediating IL-6 signaling. While IL6ST heterodimerizes with IL6RA, IL-11, IL-27, oncostatin M, and leukemia inhibitory factor receptors, IL6RA heterodimerizes exclusively with IL6ST to confer IL-6 signaling. As GATA2-dependent repression is not well understood, we devised a multi-omics strategy to elucidate mechanisms underlying repression and applied the approach to the cytokine/chemokine receptor gene family. Identifying accessible distal and intronic chromatin sites in GATA2-deficient (GATA2

Indexed as

Enhancer Elements, GeneticGATA2 Transcription FactorInflammationSignal TransductionAnimalsChromatinCytokine Receptor gp130Hematopoietic Stem CellsHumansInterleukin-6MiceMice, Inbred C57BLProto-Oncogene ProteinsReceptors, Interleukin-6Trans-ActivatorsChromatinCytokine Receptor gp130Gata2 protein, mouseGATA2 Transcription FactorInterleukin-6Proto-Oncogene ProteinsReceptors, Interleukin-6Trans-ActivatorschromatinCP: ImmunologyCP: Stem cell researchenhancerGATA2IL-27IL-6inflammationmyeloidprogenitorPU.1receptor

Identifiers

PMID41004342
PMCPMC12580906

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.